Eversept Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Eversept Partners’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.9M	Buy	196,532 +66,958	+52%	+$3.72M	0.62%	42
2026 Q1	$7.53M	Sell	129,574 -101,806	-44%	-$4.69M	0.4%	51
2025 Q4	$10.4M	Buy	+231,380	New	+$9.72M	0.52%	50
2025 Q1	–	Sell	-155,540	Closed	-$6.1M	–	73
2024 Q4	$6.1M	Buy	+155,540	New	+$6.43M	0.54%	37
2023 Q3	–	Sell	-171,378	Closed	-$6.6M	–	78
2023 Q2	$6.6M	Sell	171,378 -31,894	-16%	-$1.27M	0.55%	36
2023 Q1	$7.28M	Sell	203,272 -72,432	-26%	-$2.68M	0.51%	35
2022 Q4	$10.9M	Buy	275,704 +16,092	+6%	+$586K	0.95%	23
2022 Q3	$9.37M	Sell	259,612 -206,299	-44%	-$7.42M	0.81%	28
2022 Q2	$14.2M	Buy	465,911 +55,890	+14%	+$1.69M	1.01%	31
2022 Q1	$12.5M	Buy	410,021 +200,502	+96%	+$6M	0.96%	31
2021 Q4	$6.55M	Buy	+209,519	New	+$6.26M	0.42%	58
2020 Q2	–	Sell	-71,591	Closed	-$812K	–	79
2020 Q1	$812K	Sell	71,591 -144,018	-67%	-$2.05M	0.2%	47
2019 Q4	$2.83M	Hold	215,609	–	–	0.5%	38
2019 Q3	$1.94M	Sell	215,609 -8,731	-4%	-$82.6K	0.6%	36
2019 Q2	$2.21M	Hold	224,340	–	–	0.62%	34
2019 Q1	$2.28M	Buy	224,340 +19,236	+9%	+$163K	0.66%	29
2018 Q4	$1.29M	Sell	205,104 -4,635	-2%	-$41.2K	0.7%	30
2018 Q3	$2.77M	Buy	+209,739	New	+$2.43M	1.22%	18

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Eversept Partners's XENE Position: Q2 2026 in Review

Eversept Partners increased its Xenon Pharmaceuticals (XENE) stake by 52% in Q2 2026, buying an estimated $3.72M and bringing the position to 196,532 shares worth $11.9M. The position accounts for 0.62% of the portfolio, ranked #42.

Eversept Partners first reported a position in XENE in Q3 2018 and has held it in 18 quarters since. The position peaked at $14.2M in Q2 2022. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Eversept Partners held 196,532 shares of Xenon Pharmaceuticals worth $11.9M as of Q2 2026.
Eversept Partners bought 66,958 Xenon Pharmaceuticals shares in Q2 2026, an estimated $3.72M.
Xenon Pharmaceuticals made up 0.62% of Eversept Partners's portfolio in Q2 2026, its #42 holding.
Eversept Partners first reported a position in Xenon Pharmaceuticals in Q3 2018 and has held it in 18 quarters since.
Eversept Partners's Xenon Pharmaceuticals position peaked at $14.2M in Q2 2022.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.